Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 2/20 | 0.32 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.31 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.31 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.31 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223189 | 0.86 | HRH1 (0.44) | SRCZAP70SYKCDK2HRH1 | |
| SCHEMBL22222428 | 0.84 | HRH1 (0.34) | HRH1PTPRB | |
| SCHEMBL8128248 | 0.84 | HRH1 (0.34) | SRCZAP70SYKCDK2HRH1 | |
| SCHEMBL128381 | 0.82 | HRH1 (0.33) | HRH1 | |
| SCHEMBL17018481 | 0.82 | HRH1 (0.33) | SRCZAP70SYKCDK2HRH1 | |
| SCHEMBL17018485 | 0.82 | HRH1 (0.33) | SRCZAP70SYKCDK2HRH1 | |
| SCHEMBL16603243 | 0.82 | F2RL3 (0.35) | SRCZAP70SYKCDK2HRH1 | |
| SCHEMBL16603245 | 0.81 | F2RL3 (0.33) | SRCZAP70SYKCDK2HRH1 | |
| SCHEMBL1614025 | 0.80 | SRC (0.31) | SRCZAP70SYKCDK2HRH1 | |
| SCHEMBL21962666 | 0.79 | NPC1 (0.34) | HRH1PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021002887-A1 | GUT-TARGETED NLRP3 ANTAGONISTS AND THEIR USE IN THERAPY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |